ストックスクリーナーアプリを入手
9.11
0.22%
0.02
前日終値:
$9.09
開ける：
$9.08
24時間の取引高:
97,232
Relative Volume:
0.80
時価総額：
$850.94M
収益：
$106.66M
当期純損益:
$15.16M
株価収益率:
97.43
EPS:
0.0935
ネットキャッシュフロー:
$6.37M
1週間 パフォーマンス:
-6.18%
1か月 パフォーマンス:
-19.31%
6か月 パフォーマンス:
-28.61%
1年 パフォーマンス:
-47.88%
1日の値動き範囲:
$8.87
$9.36
1週間の範囲:
$8.65
$9.975
52週間の値動き範囲:
$8.26
$19.00
Gyre Therapeutics Inc Stock (GYRE) Company Profile
名前
Gyre Therapeutics Inc
セクター
電話
(619) 949-3681
住所
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
GYRE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
9.11 | 850.94M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
すべてを表示
Gyre Therapeutics Inc (GYRE) 最新ニュース
Gyre Therapeutics announces publication of protocol for Phase 3 trial on F351 - TipRanks
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance
Major Breakthrough: New Phase 3 Trial Targets Chronic Hepatitis B Liver Fibrosis Treatment - StockTitan
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells common stock for $1,740 - Investing.com
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.7% – Here’s Why - Defense World
Gyre therapeutics president Ma Songjiang sells $40,440 in stock By Investing.com - Investing.com Canada
Gyre therapeutics president Ma Songjiang sells $40,440 in stock - Investing.com India
GyreIntriguing Upcoming Data Catalyst, But I'm Still On Sidelines (NASDAQ:GYRE) - Seeking Alpha
Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings - TipRanks
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock - Investing.com
Gyre Therapeutics president Ma Songjiang sells $26,658 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Gyre Therapeutics Inc (GYRE) Q4 2024 Earnings: Revenue Surpasses Estimates at $27.9M, EPS Misses at $0.00 - GuruFocus.com
Impact of New U.S. Regulations on Gyre Therapeutics: Potential Delisting Risks and Investor Concerns - TipRanks
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down on Disappointing Earnings - Defense World
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics (GYRE) Projected to Post Earnings on Tuesday - Defense World
Decoding Gyre Therapeutics Inc (GYRE): A Strategic SWOT Insight - GuruFocus.com
Gyre Therapeutics offers weak 2025 revenue guidance - Investing.com India
Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com - Investing.com Canada
Gyre Therapeutics Reports Breakeven in Q4 as Revenue Increases -March 17, 2025 at 04:52 pm EDT - Marketscreener.com
(GYRE) Gyre Therapeutics Sees 2025 Revenue Range $118M$128M -March 17, 2025 at 04:18 pm EDT - Marketscreener.com
FY2024 Earnings Forecast for GYRE Issued By Noble Financial - Defense World
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock By Investing.com - Investing.com Canada
Gyre Therapeutics president Ma Songjiang sells $46,280 in stock - Investing.com India
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Exploring High Growth Tech Stocks In The US March 2025 - Simply Wall St
Gyre therapeutics president Ma Songjiang sells $40,776 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial - Defense World
Gyre therapeutics president Ma Songjiang sells $40,776 in stock - Investing.com
Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target - Marketscreener.com
Gyre Therapeutics initiated with an Outperform at Noble Capital - TipRanks
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Still a Buy? - Defense World
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock - Investing.com India
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Ma Songjiang sells $44,180 in stock - Investing.com
Gyre Therapeutics president Ma Songjiang sells $44,180 in stock By Investing.com - Investing.com UK
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
Gyre Therapeutics president Ma Songjiang sells $45,480 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Ma Songjiang sells $45,480 in stock - Investing.com India
Public companies in Gyre Therapeutics, Inc. (NASDAQ:GYRE) are its biggest bettors, and their bets paid off as stock gained 10.0% last week - Simply Wall St
Gyre Therapeutics president Ma Songjiang sells shares for $42,860 - MSN
Gyre Therapeutics (NASDAQ:GYRE) Trading 7.6% HigherShould You Buy? - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 9.1%What's Next? - MarketBeat
Gyre Therapeutics Inc (GYRE) 財務データ
収益
当期純利益
現金流量
EPS
Gyre Therapeutics Inc (GYRE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
Mar 19 '25 |
Sale |
10.13 |
2,000 |
20,260 |
2,827,018 |
| Ma Songjiang | President |
Mar 20 '25 |
Sale |
10.09 |
2,000 |
20,180 |
2,825,018 |
| Ma Songjiang | President |
Mar 17 '25 |
Sale |
12.09 |
2,000 |
24,180 |
2,829,260 |
| Ma Songjiang | President |
Mar 18 '25 |
Sale |
10.24 |
242 |
2,478 |
2,829,018 |
| Ma Songjiang | President |
Mar 14 '25 |
Sale |
12.31 |
2,000 |
24,620 |
2,831,260 |
| Ma Songjiang | President |
Mar 13 '25 |
Sale |
11.80 |
2,000 |
23,600 |
2,833,260 |
| Ma Songjiang | President |
Mar 12 '25 |
Sale |
11.74 |
2,000 |
23,480 |
2,835,260 |
| Ma Songjiang | President |
Mar 11 '25 |
Sale |
11.40 |
2,000 |
22,800 |
2,837,260 |
| Ma Songjiang | President |
Mar 07 '25 |
Sale |
10.25 |
2,000 |
20,496 |
2,841,260 |
| Ma Songjiang | President |
Mar 10 '25 |
Sale |
10.14 |
2,000 |
20,280 |
2,839,260 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):